绥美凯如何使用？

The treatment plan is based on DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and made into a single-tablet treatment for promotion, which has made great progress in the HAART treatment of core drugs. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work. It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Today we will learn how to use Suimeikai?

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

Recommended dosage:

Adults and Adolescents (weighing at least 40 kg): For adults and adolescents, the recommended dose of Sumax is one tablet, once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced. 

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines. 

If you miss a dose:

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

  For elderly patients:

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

  Patients with renal impairment: Patients with creatinine clearance less than 50mL/min are not recommended to take Suimeikai. 

Patients with liver damage:

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Trimax is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.

The above is the usage method, I hope it can help you!